ALGN vs. VRTX: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALGN and VRTX, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
VRTX stands out with 111.79 billion USD in market value—about 8.97× ALGN’s market cap of 12.46 billion USD.
ALGN’s beta of 1.68 points to much larger expected swings compared to VRTX’s calmer 0.51, suggesting both higher upside and downside potential.
| Symbol | ALGN | VRTX |
|---|---|---|
| Company Name | Align Technology, Inc. | Vertex Pharmaceuticals Incorporated |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Devices | Biotechnology |
| CEO | Mr. Joseph M. Hogan | Dr. Reshma Kewalramani FASN, M.D. |
| Price | 171.91 USD | 435.32 USD |
| Market Cap | 12.46 billion USD | 111.79 billion USD |
| Beta | 1.68 | 0.51 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | January 30, 2001 | July 24, 1991 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALGN and VRTX over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALGN and VRTX based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- VRTX shows a negative P/E of -113.09, highlighting a year of losses, whereas ALGN at 30.88 trades on solid profitability.
- VRTX shows a negative forward PEG of -9.08, signaling expected earnings contraction, while ALGN at 2.92 maintains analysts’ projections for stable or improved profits.
- VRTX reports a negative Price-to-Free Cash Flow ratio of -88.86, showing a cash flow shortfall that could threaten its operational sustainability, while ALGN at 19.76 maintains positive cash flow.
| Symbol | ALGN | VRTX |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 30.88 | -113.09 |
| Forward PEG Ratio (TTM) | 2.92 | -9.08 |
| Price-to-Sales Ratio (P/S, TTM) | 3.13 | 10.07 |
| Price-to-Book Ratio (P/B, TTM) | 3.33 | 6.78 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 19.76 | -88.86 |
| EV-to-EBITDA (TTM) | 14.56 | -1425.47 |
| EV-to-Sales (TTM) | 2.94 | 9.80 |
| EV-to-Free Cash Flow (TTM) | 18.56 | -86.46 |
Dividend Comparison
Neither ALGN nor VRTX currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ALGN | VRTX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALGN and VRTX, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ALGN shows “--” (minimal interest expense), but VRTX is in the red with interest coverage -32.00, signaling a net operating loss.
| Symbol | ALGN | VRTX |
|---|---|---|
| Current Ratio (TTM) | 1.21 | 2.65 |
| Quick Ratio (TTM) | 1.08 | 2.29 |
| Debt-to-Equity Ratio (TTM) | 0.03 | 0.10 |
| Debt-to-Assets Ratio (TTM) | 0.02 | 0.07 |
| Interest Coverage Ratio (TTM) | -- | -32.00 |